IVF Reads / Ovulation Induction: Letrozole, Clomiphene and Injections Compared

Ovulation Induction: Letrozole, Clomiphene and Injections Compared

M
Written by MayaPublished Updated
IVFPulse blog image
AI summary

Ovulation induction is treatment to make the ovaries release a single egg in women who are not ovulating, most often because of PCOS. The 2023 International PCOS Guideline (Teede et al., Hum Reprod 2023) makes letrozole the first-line drug, with clomiphene, clomiphene plus metformin, injected gonadotrophins or ovarian surgery as alternatives or second line, and IVF third line. In the 2022 Cochrane review (Franik et al.; 11 trials, 2,060 women) letrozole raised live birth over clomiphene-type drugs (odds ratio 1.72), so a 20% chance becomes 27% to 35%, with the same 0.5% rate of ovarian hyperstimulation. Over the full sequence of tablets then injections, 60% of 108 anovulatory women with PCOS in a Dutch cohort had a singleton live birth within 12 months and 78% within 24 months (Veltman-Verhulst 2012). NICE NG257 (2026) advises against ovarian stimulation on its own for unexplained infertility.

  • Who it is for: anovulatory infertility with no other infertility factor (Teede 2023). Hypothalamic causes are treated with gonadotrophins with LH activity or GnRH, and high prolactin with cabergoline (NICE NG257, 2026, recs 1.30.2 and 1.32.1).
  • Letrozole versus clomiphene, PCOS: live birth OR 1.72 (95% CI 1.40 to 2.11; 11 RCTs, 2,060 women; high certainty); OHSS 0.5% in both arms; multiple pregnancy 1.6% versus 2.2%, not significantly different (Franik et al., Cochrane 2022, CD010287.pub4). Largest single trial: cumulative live birth over up to five cycles 27.5% (103 of 374) versus 19.1% (72 of 376) (Legro et al., NEJM 2014).
  • Indian data: at AIIMS New Delhi (Roy et al. 2012; 204 women, up to three cycles) 43.8% of women on letrozole and 26.4% on clomiphene became pregnant; pregnancy per cycle 14.6% versus 8.8%. Live birth was not the primary outcome.
  • After clomiphene fails: in M-OVIN (Weiss et al., Lancet 2018; 661 women not pregnant after six ovulatory clomiphene cycles), live birth within eight months was 52% (167 of 327) on gonadotrophins versus 41% (138 of 334) on continued clomiphene, RR 1.24; the 2025 Cochrane review (Weiss et al., CD010290.pub4) rates this moderate certainty and finds little or no difference between recombinant and urinary FSH.
  • Over time: cumulative singleton live birth 60% at 12 months and 78% at 24 months in 108 treatment-naive anovulatory women with PCOS treated with clomiphene then gonadotrophins (Veltman-Verhulst et al., Fertil Steril 2012); 56% of 240 women in the earlier cohort (Eijkemans et al., Hum Reprod 2003). Older age, longer infertility and higher BMI or insulin predicted lower chances.

Who is ovulation induction for, and what does it actually do?

Ovulation induction is medicine that makes the ovaries release an egg in a woman who is not ovulating, or ovulating only now and then. The aim is one egg, released inside the body, followed by sex at the right time. It is not the same as IVF stimulation, which deliberately grows many eggs to collect.

The commonest reason for needing it is polycystic ovary syndrome (PCOS). The 2023 International PCOS Guideline frames these treatments for women whose only fertility problem is not ovulating: tubes open and a partner's semen analysis acceptable. Other causes of not ovulating need different treatment. NICE's 2026 fertility guideline (NG257) recommends injected hormones or GnRH for women whose brain signal to the ovaries is low (hypogonadotropic hypogonadism), advising them that reaching a healthy weight and moderating heavy exercise may help, and cabergoline when high prolactin is the cause. Working out which cause applies comes first; our guide to why ovulation stops sets out the tests.

When is ovulation induction the wrong treatment?

If you already ovulate, making you ovulate harder is not the answer. For couples with unexplained infertility, NICE NG257 says plainly: do not offer ovarian stimulation as a stand-alone treatment. After two years of trying, NICE suggests up to four cycles of IUI with ovarian stimulation or going to IVF, and the 2023 ESHRE guideline on unexplained infertility likewise recommends IUI with ovarian stimulation as the first-line treatment.

It also cannot fix blocked tubes or a significant sperm problem, because the egg still has to meet sperm in a working tube. The PCOS guideline advises deciding case by case whether to test the tubes before starting. Sometimes the answer is testing, timing or a different treatment, not more tablets. For couples where nothing has been found, see unexplained infertility; for the step beyond, IUI versus IVF.

Letrozole or clomiphene: which comes first?

For PCOS, letrozole. The 2023 International PCOS Guideline makes it the first-line tablet, at its highest level of certainty, because in head-to-head trials more women on letrozole had a baby than on clomiphene. The guideline notes that letrozole is used off-label in many countries, and that it should not be started if there is any chance of an existing pregnancy.

Clomiphene still works and is still used, alone or with metformin, which in a 2019 pooled analysis of trial data raised pregnancy rates a little but did not clearly raise live births. Clomiphene raises the chance of twins, so the guideline says clomiphene cycles may need ultrasound monitoring. If you are already on it, our guide to Clomid covers side effects and cycle limits. The same comparison has been run in India: at AIIMS New Delhi, about four in ten women on letrozole became pregnant within three cycles, against about one in four on clomiphene.

Letrozole versus clomiphene-type drugs, women with PCOS20% → 27–35%If 20% of women would have a live birth on clomiphene-type drugs, 27% to 35% would on letrozole (odds ratio 1.72, 95% CI 1.40 to 2.11; 11 randomised trials, 2,060 women; high certainty). Ovarian hyperstimulation 0.5% in both arms; multiple pregnancy 1.6% versus 2.2%, not significantly different.Franik et al., Cochrane Database Syst Rev 2022, CD010287.pub4 (PMID 36165742). Ovulation induction followed by intercourse.
Largest single trial: live birth over up to five cycles27.5% vs 19.1%Cumulative live birth with letrozole, 103 of 374 women, versus clomiphene, 72 of 376 (rate ratio 1.44, 95% CI 1.10 to 1.87). Ovulation in 61.7% versus 48.3% of treatment cycles. Women aged 18 to 40 with PCOS, at least one open tube and a partner with an acceptable sperm count.Legro et al., N Engl J Med 2014;371:119-29 (PMID 25006718; PMC4175743, which carries the journal's correction notice).
An Indian trial: AIIMS New Delhi, up to three cycles43.8% vs 26.4%Women who became pregnant: 43 of 98 on letrozole versus 28 of 106 on clomiphene. Pregnancy per cycle 14.6% versus 8.8%. Ovulation was similar (85.7% versus 86.7% of women). Pregnancy, not live birth, was the outcome.Roy et al., J Hum Reprod Sci 2012;5:20-5 (PMID 22870010, PMC3409915); one of seven Indian trials in the 2022 Cochrane review.

What happens in a treatment cycle?

Before the first cycle, pregnancy should be ruled out, and the PCOS guideline advises starting prenatal vitamins. The tablets are taken for a few days early in the cycle. Your clinic then checks whether an egg has grown and been released, usually with ultrasound scans and sometimes blood tests, and tells you which days to have sex. Some clinics add a trigger injection to time the release.

Monitoring is there to catch two things: no response, so the next cycle can be adjusted, and too many follicles, the main route to twins and triplets. On injections, if more than two follicles grow large, the PCOS guideline advises cancelling the cycle or avoiding unprotected sex that month. It is frustrating to lose a month that way, and it is still the safer choice.

Each month without a pregnancy is hard, even when you know the odds are counted over several cycles. That is worth saying to your doctor and your partner, not carrying alone.

Want your own results explained?

IVY can read your reports alongside your history and set out what the evidence supports for your situation — and what it does not.

What are the odds, per cycle and over time?

A single cycle has modest odds, and that is why per-cycle numbers can sound discouraging. The more useful number is what happens to women who keep going through the usual sequence of tablets and then injections. In two Dutch studies that followed women with irregular or absent ovulation from their first treatment, most had a baby, and the chance fell with older age, longer time trying, and higher weight or insulin levels.

Tablets, then injections: singleton live birth over time60% at 1 year, 78% at 2 yearsCumulative singleton live birth in 108 treatment-naive women with anovulatory PCOS, treated with clomiphene first and gonadotrophin injections second, at a tertiary unit. In an earlier cohort of 240 similar women, 56% had a singleton live birth.Veltman-Verhulst et al., Fertil Steril 2012;98:761-8 (PMID 22633255); Eijkemans et al., Hum Reprod 2003;18:2357-62 (PMID 14585887). Netherlands; predates letrozole as first line.

What if the tablets do not work?

The second step is usually daily hormone injections (gonadotrophins), or for some women with PCOS keyhole surgery on the ovaries. The PCOS guideline asks for a low-dose, slowly increased injection plan aimed at one follicle, with closer ultrasound monitoring, and notes that injections give higher live birth rates than surgery but more multiple pregnancies. IVF is the third step, once the earlier steps have failed and there is no other reason to go straight to it.

Moving to injections helps. In a Dutch trial of women who had ovulated on clomiphene for six cycles without conceiving, more had a baby within eight months after switching to injections than after continuing clomiphene, without more twins.

After six ovulatory clomiphene cycles without pregnancy52% vs 41%Live birth within eight months: 167 of 327 women switched to gonadotrophins versus 138 of 334 who continued clomiphene (relative risk 1.24, 95% CI 1.05 to 1.46). Multiple pregnancy rates low and not different.Weiss et al. (M-OVIN), Lancet 2018;391:758-65 (PMID 29273245); rated moderate certainty in Weiss et al., Cochrane Database Syst Rev 2025, CD010290.pub4 (PMID 40193219).

What are the risks?

The main risk is more than one baby. The risk is higher with injections than with tablets, which is why NICE asks clinics to explain the risk of multiple pregnancy and ovarian hyperstimulation before injections start and to use ultrasound throughout. Ovarian hyperstimulation, where the ovaries over-respond, was seen in 0.5% of women on either tablet in the 2022 Cochrane review (10 trials, 1,848 participants); our OHSS guide lists the symptoms that need a call to the clinic.

What the evidence does not establish

  • Whether the PCOS results transfer to Indian women as a group. The largest live-birth trials cited here were run in the US and the Netherlands; the Indian trials found here are small and measured pregnancy, not babies born.
  • What the odds are over time with letrozole first. The one-year and two-year figures above come from Dutch cohorts that started with clomiphene.
  • How clomiphene compares with no treatment on live birth. The Cochrane review of clomiphene (Brown 2016) found no live-birth data against placebo, and its pregnancy data were low quality.
  • Whether some unfavourable letrozole trials are missing. The 2022 Cochrane review saw mild funnel-plot asymmetry suggesting trials favouring clomiphene might be missing, and removed several trials over data-validity concerns.
  • Long-term safety for mother or child. This page did not review that evidence and makes no claim either way.

Not sure what your results mean?

Upload your test results and IVY will explain what has been checked, what it shows, and what usually comes next.

Keep reading

14 Sources

  1. Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655-1679. PMID 37580037. ESHRE / ASRM / Monash University (Human Reproduction)
  2. National Institute for Health and Care Excellence. Fertility problems: assessment and treatment (NG257), published 31 March 2026. Management of female factor fertility problems, recs 1.30-1.33. NICE
  3. National Institute for Health and Care Excellence. Fertility problems: assessment and treatment (NG257), 2026. Unexplained fertility problems, recs 1.38.1-1.38.3. NICE
  4. Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022;9:CD010287. PMID 36165742. Cochrane
  5. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-129. PMID 25006718. New England Journal of Medicine
  6. Roy KK, Baruah J, Singla S, et al. A prospective randomized trial comparing the efficacy of letrozole and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012;5(1):20-25. PMID 22870010. Journal of Human Reproductive Sciences (AIIMS New Delhi)
  7. Weiss NS, Nahuis MJ, Bordewijk E, et al. Gonadotrophins versus clomifene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomifene failure (M-OVIN). Lancet. 2018;391:758-765. PMID 29273245. The Lancet
  8. Weiss NS, Kostova EB, Mol BWJ, van Wely M. Gonadotropins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2025;4:CD010290. PMID 40193219. Cochrane
  9. Veltman-Verhulst SM, Fauser BC, Eijkemans MJ. High singleton live birth rate confirmed after ovulation induction in women with anovulatory polycystic ovary syndrome. Fertil Steril. 2012;98(3):761-768.e1. PMID 22633255. Fertility and Sterility
  10. Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod. 2003;18(11):2357-2362. PMID 14585887. Human Reproduction
  11. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551-566. PMID 17287476. New England Journal of Medicine
  12. Wang R, Li W, Bordewijk EM, et al. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update. 2019;25(6):717-732. PMID 31647106. Human Reproduction Update
  13. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database Syst Rev. 2016;12:CD002249. PMID 27976369. Cochrane
  14. ESHRE Guideline Group on Unexplained Infertility. Evidence-based guideline: unexplained infertility. Hum Reprod. 2023;38(10):1881-1890. PMID 37599566. ESHRE

Frequently asked questions

Common questions on this topic.

Is ovulation induction the same as the stimulation used in IVF?

No. Ovulation induction aims for one egg released naturally, with sex or insemination timed around it. IVF stimulation grows many eggs so they can be collected and fertilised in the laboratory. The 2023 PCOS guideline asks for low-dose injection plans in ovulation induction specifically to favour a single follicle.

Does adding IUI to ovulation induction improve the chances?

Not clearly, when not ovulating is the only problem. In the Dutch M-OVIN trial (Lancet 2018) of women who had not conceived after six ovulatory clomiphene cycles, live birth was 49% with IUI versus 43% with timed intercourse, a difference that was not statistically significant. IUI with stimulation is a first-line option for unexplained infertility under ESHRE's 2023 guideline, which is a different situation.

Does the type of injection matter?

Probably not much. The 2025 Cochrane review of gonadotrophins for women with PCOS found little or no difference in live birth, multiple pregnancy or miscarriage between recombinant and urinary-derived FSH (low-certainty evidence). The monitoring and how cautiously the dose is raised matter more for safety.

Is metformin on its own enough to start ovulating?

It is the weakest of the options for getting pregnant. In a US trial of 626 women with PCOS (Legro et al., NEJM 2007), live birth over up to six months was 7.2% with metformin alone, 22.5% with clomiphene and 26.8% with both. The 2023 guideline prefers clomiphene over metformin alone.

Should I lose weight before starting?

The 2023 PCOS guideline asks doctors to discuss how excess weight lowers pregnancy and live birth rates and raises miscarriage after fertility treatment, while rating that evidence very low certainty and warning against weight stigma. Whether to wait is a decision to make with your doctor, weighing age and time already spent trying.

Does letrozole cause birth defects?

The 2023 PCOS guideline found no difference in fetal abnormality rates between letrozole, clomiphene and natural conception. In the largest trial (Legro 2014) there were four major anomalies with letrozole and one with clomiphene, a difference that was not statistically significant.